Literature DB >> 8445720

Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation.

B Tomkinson1, E Robertson, E Kieff.   

Abstract

Recombinant Epstein-Barr viruses (EBV) with a translation termination codon mutation inserted into the nuclear protein 3A (EBNA-3A) or 3C (EBNA-3C) open reading frame were generated by second-site homologous recombination. These mutant viruses were used to infect primary B lymphocytes to assess the requirement of EBNA-3A or -3C for growth transformation. The frequency of obtaining transformants infected with a wild-type EBNA-3A recombinant EBV was 10 to 15%. In contrast, the frequency of obtaining transformants infected with a mutant EBNA-3A recombinant EBV was only 1.4% (9 mutants in 627 transformants analyzed). Transformants infected with mutant EBNA-3A recombinant virus could be obtained only by coinfection with another transformation-defective EBV which provided wild-type EBNA-3A in trans. Cells infected with mutant EBNA-3A recombinant virus lost the EBNA-3A mutation with expansion of the culture. The decreased frequency of recovery of the EBNA-3A mutation, the requirement for transformation-defective EBV coinfection, and the inability to maintain the EBNA-3A mutation indicate that EBNA-3A is essential or critical for lymphocyte growth transformation and that the EBNA-3A mutation has a partial dominant negative effect. Five transformants infected with mutant EBNA-3C recombinant virus EBV were also identified and expanded. All five also required wild-type EBNA-3C in trans. Serial passage of the mutant recombinant virus into primary B lymphocytes resulted in transformants only when wild-type EBNA-3C was provided in trans by coinfection with a transformation-defective EBV carrying a wild-type EBNA-3C gene. A secondary recombinant virus in which the mutated EBNA-3C gene was replaced by wild-type EBNA-3C was able to transform B lymphocytes. Thus, EBNA-3C is also essential or critical for primary B-lymphocyte growth transformation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8445720      PMCID: PMC240270     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

1.  Biological differences between Epstein-Barr virus (EBV) strains with regard to lymphocyte transforming ability, superinfection and antigen induction.

Authors:  J Menezes; W Leibold; G Klein
Journal:  Exp Cell Res       Date:  1975-05       Impact factor: 3.905

2.  Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma.

Authors:  J Menezes; W Leibold; G Klein; G Clements
Journal:  Biomedicine       Date:  1975-07

3.  Nasopharyngeal carcinoma. X. Presence of epstein-barr genomes in separated epithelial cells of tumours in patients from Singapore, Tunisia and Kenya.

Authors:  C Desgranges; H Wolf; G De-Thé; K Shanmugaratnam; N Cammoun; R Ellouz; G Klein; K Lennert; N Muñoz; H Zur Hausen
Journal:  Int J Cancer       Date:  1975-07-15       Impact factor: 7.396

4.  Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes.

Authors:  G Miller; T Shope; H Lisco; D Stitt; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1972-02       Impact factor: 11.205

5.  EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx.

Authors:  H zur Hausen; H Schulte-Holthausen; G Klein; W Henle; G Henle; P Clifford; L Santesson
Journal:  Nature       Date:  1970-12-12       Impact factor: 49.962

6.  A survey of Epstein-Barr virus DNA in lymphoid tissue. Frequent detection in Hodgkin's disease.

Authors:  S P Staal; R Ambinder; W E Beschorner; G S Hayward; R Mann
Journal:  Am J Clin Pathol       Date:  1989-01       Impact factor: 2.493

7.  Release of infectious Epstein-Barr virus by transformed marmoset leukocytes.

Authors:  G Miller; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1973-01       Impact factor: 11.205

8.  Malignant lymphoma in cottontop marmosets after inoculation with Epstein-Barr virus.

Authors:  T Shope; D Dechairo; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1973-09       Impact factor: 11.205

9.  Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference.

Authors:  G Miller; J Robinson; L Heston; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1974-10       Impact factor: 11.205

10.  Surface markers on human B and T lymphocytes. II. Presence of Epstein-Barr virus receptors on B lymphocytes.

Authors:  M Jondal; G Klein
Journal:  J Exp Med       Date:  1973-12-01       Impact factor: 14.307

View more
  182 in total

1.  Genetic dissection of cell growth arrest functions mediated by the Epstein-Barr virus lytic gene product, Zta.

Authors:  A Rodriguez; M Armstrong; D Dwyer; E Flemington
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Structural, functional, and genetic comparisons of Epstein-Barr virus nuclear antigen 3A, 3B, and 3C homologues encoded by the rhesus lymphocryptovirus.

Authors:  H Jiang; Y G Cho; F Wang
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

Review 3.  Signaling activities of gammaherpesvirus membrane proteins.

Authors:  B Damania; J K Choi; J U Jung
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  Epstein-Barr virus recombinants from BC-1 and BC-2 can immortalize human primary B lymphocytes with different levels of efficiency and in the absence of coinfection by Kaposi's sarcoma-associated herpesvirus.

Authors:  A J Aguirre; E S Robertson
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

5.  Interferon regulatory factor 2 represses the Epstein-Barr virus BamHI Q latency promoter in type III latency.

Authors:  L Zhang; J S Pagano
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

Review 6.  The genetic approach to the Epstein-Barr virus: from basic virology to gene therapy.

Authors:  H J Delecluse; W Hammerschmidt
Journal:  Mol Pathol       Date:  2000-10

7.  Determining the role of the Epstein-Barr virus Cp EBNA2-dependent enhancer during the establishment of latency by using mutant and wild-type viruses recovered from cottontop marmoset lymphoblastoid cell lines.

Authors:  L Yoo; S H Speck
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

8.  Modulation of histone acetyltransferase activity through interaction of epstein-barr nuclear antigen 3C with prothymosin alpha.

Authors:  M A Cotter; E S Robertson
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

9.  Conserved region CR2 of Epstein-Barr virus nuclear antigen leader protein is a multifunctional domain that mediates self-association as well as nuclear localization and nuclear matrix association.

Authors:  Michiko Tanaka; Akihiko Yokoyama; Mie Igarashi; Go Matsuda; Kentaro Kato; Mikiko Kanamori; Kanji Hirai; Yasushi Kawaguchi; Yuji Yamanashi
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

10.  Physical and functional interactions between the corepressor CtBP and the Epstein-Barr virus nuclear antigen EBNA3C.

Authors:  R Touitou; M Hickabottom; G Parker; T Crook; M J Allday
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.